BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059-3068. [PMID: 25838346 DOI: 10.1182/blood-2014-11-568907] [Cited by in Crossref: 178] [Cited by in F6Publishing: 166] [Article Influence: 25.4] [Reference Citation Analysis]
Number Citing Articles
1 Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181:11-26. [PMID: 29265356 DOI: 10.1111/bjh.15075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
2 Orfao A. Issue Highlights - May 2019. Cytometry B Clin Cytom 2019;96:177-80. [PMID: 31091004 DOI: 10.1002/cyto.b.21786] [Reference Citation Analysis]
3 Soh KT, Tario JD, Wallace PK. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. Clin Lab Med. 2017;37:821-853. [PMID: 29128071 DOI: 10.1016/j.cll.2017.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematology Am Soc Hematol Educ Program 2017;2017:498-507. [PMID: 29222298 DOI: 10.1182/asheducation-2017.1.498] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
5 Moreau P, Zamagni E. MRD in multiple myeloma: more questions than answers? Blood Cancer J 2017;7:639. [PMID: 29209089 DOI: 10.1038/s41408-017-0028-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
6 Nair AP, Walker P, Kalff A, Bergin K, Hocking J, Avery S, Curtis DJ, Patil S, Das T, Klarica D, Morgan S, Muirhead J, Gorniak M, Reynolds J, Spencer A. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. Bone Marrow Transplant 2017;52:839-45. [DOI: 10.1038/bmt.2017.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Anderson KC. Should minimal residual disease negativity be the end point of myeloma therapy? Blood Adv 2017;1:517-21. [PMID: 29296970 DOI: 10.1182/bloodadvances.2016000117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
8 Ho C, Syed M, Roshal M, Petrova-Drus K, Moung C, Yao J, Quesada AE, Benhamida J, Vanderbilt C, Liu Y, Zhu M, Yu W, Maciag L, Wang M, Ma Y, Gao Q, Rustad EH, Hultcrantz M, Diamond BT, Zheng-Lin B, Huang Y, Hutt K, Miller JE, Dogan A, Nafa K, Landgren O, Arcila ME. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry. J Mol Diagn 2021;23:181-99. [PMID: 33217553 DOI: 10.1016/j.jmoldx.2020.10.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Braunstein M, Niesvizky R. Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma. Seminars in Oncology 2016;43:709-11. [DOI: 10.1053/j.seminoncol.2016.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Minarik J, Novak M, Flodr P, Balcarkova J, Mlynarcikova M, Krhovska P, Pika T, Pikalova Z, Bacovsky J, Scudla V. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy. Eur J Haematol 2017;99:186-9. [PMID: 28470777 DOI: 10.1111/ejh.12902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
11 Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, Scheid C, Luttmann S, Emrich K, Holleczek B, Katalinic A, Nennecke A, Straka C, Langer C, Engelhardt M, Einsele H, Kröger N, Beelen D, Dreger P, Brenner H, Goldschmidt H. Survival of elderly patients with multiple myeloma—Effect of upfront autologous stem cell transplantation. European Journal of Cancer 2016;62:1-8. [DOI: 10.1016/j.ejca.2016.04.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
12 Li H, Li F, Zhou X, Mei J, Song P, An Z, Zhao Q, Guo X, Wang X, Zhai Y. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis. Ann Hematol 2019;98:1185-95. [PMID: 30721336 DOI: 10.1007/s00277-019-03609-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
13 Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica 2020;105:2358-67. [PMID: 33054076 DOI: 10.3324/haematol.2020.247015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
14 Tovar N, Rodríguez-lobato LG, Cibeira MT, Magnano L, Isola I, Rosiñol L, Bladé J, Fernández de Larrea C. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. Amyloid 2018;25:79-85. [DOI: 10.1080/13506129.2018.1443439] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
15 Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 2017;281:365-82. [DOI: 10.1111/joim.12590] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 14.4] [Reference Citation Analysis]
16 Vyas SG, Singh G. Prospective Identification of Oligoclonal/Abnormal Band of the Same Immunoglobulin Type as the Malignant Clone by Differential Location of M-Spike and Oligoclonal Band. J Clin Med Res 2017;9:826-30. [PMID: 28912918 DOI: 10.14740/jocmr3109w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
17 Willrich MA, Murray DL, Kyle RA. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clinical Biochemistry 2018;51:38-47. [DOI: 10.1016/j.clinbiochem.2017.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
18 Baughn LB, Sachs Z, Noble-Orcutt KE, Mitra A, Van Ness BG, Linden MA. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. Leuk Lymphoma 2017;58:1931-40. [PMID: 27981867 DOI: 10.1080/10428194.2016.1266621] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
19 Nadiminti K, Singh Abbi KK, Mott SL, Dozeman L, Tricot A, Schultz A, Behrends S, Zhan F, Tricot G. VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. Onco Targets Ther 2017;10:217-26. [PMID: 28123303 DOI: 10.2147/OTT.S112423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
20 Nishihori T, Song J, Shain KH. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Curr Hematol Malig Rep. 2016;11:118-126. [PMID: 26898557 DOI: 10.1007/s11899-016-0308-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zhang X, Chen Y, Zhao P, Zang L, Zhang Z, Wang X. MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma. Leuk Lymphoma. 2017;58:932-940. [PMID: 27830963 DOI: 10.1080/10428194.2016.1213827] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
22 Pieri M, De Stefano A, Franceschini L, Rizzo M, Duranti F, Bernardini S, Cantonetti M, Zenobi R, Dessi M. Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry? Br J Haematol 2016;175:733-5. [DOI: 10.1111/bjh.13878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
23 Kocoglu M, Badros A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals (Basel) 2016;9:E3. [PMID: 26784207 DOI: 10.3390/ph9010003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
24 Yan X, Xu XS, Weisel KC, Mateos MV, Sonneveld P, Dimopoulos MA, Usmani SZ, Bahlis NJ, Puchalski T, Ukropec J, Bellew K, Ming Q, Sun S, Zhou H. Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Clin Transl Sci 2020;13:1345-54. [PMID: 32583948 DOI: 10.1111/cts.12836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Mithraprabhu S, Spencer A. Liquid Biopsy in Multiple Myeloma. In: Guenova M, Balatzenko G, editors. Hematology - Latest Research and Clinical Advances. InTech; 2018. [DOI: 10.5772/intechopen.72652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
26 Paul B, Lipe B, Ocio EM, Usmani SZ. Induction Therapy for Newly Diagnosed Multiple Myeloma. Am Soc Clin Oncol Educ Book 2019;39:e176-86. [PMID: 31099624 DOI: 10.1200/EDBK_238527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
27 Ouyang D, Li Y, He W, Lin W, Hu L, Wang C, Xu L, Park J, You L. Mechanical segregation and capturing of clonal circulating plasma cells in multiple myeloma using micropillar-integrated microfluidic device. Biomicrofluidics 2019;13:064114. [PMID: 31768200 DOI: 10.1063/1.5112050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Takamatsu H. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. J Clin Med. 2017;6:E91. [PMID: 28946710 DOI: 10.3390/jcm6100091] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
29 Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma. Cytometry B Clin Cytom 2016;90:73-80. [PMID: 26108351 DOI: 10.1002/cyto.b.21268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
30 Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, Sauer S, Bertsch U, Besemer B, Fenk R, Hänel M, Munder M, Weisel KC, Blau IW, Neubauer A, Müller-Tidow C, Raab MS, Goldschmidt H, Huhn S, For The German-Speaking Myeloma Multicenter Group Gmmg. Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers (Basel) 2020;12:E2322. [PMID: 32824635 DOI: 10.3390/cancers12082322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Chakraborty R, Zeldenrust S, Kumar SK, Kyle RA, Rajkumar SV, Gertz MA. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood 2017;129:82-7. [PMID: 27729322 DOI: 10.1182/blood-2016-06-721878] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
32 Sonneveld P. Should minimal residual disease negativity not be the end point of myeloma therapy? Blood Adv 2017;1:522-5. [PMID: 29296971 DOI: 10.1182/bloodadvances.2017000109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
33 Lecouvet FE, Vekemans MC, Van Den Berghe T, Verstraete K, Kirchgesner T, Acid S, Malghem J, Wuts J, Hillengass J, Vandecaveye V, Jamar F, Gheysens O, Vande Berg BC. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT. Skeletal Radiol 2021. [PMID: 34363522 DOI: 10.1007/s00256-021-03841-5] [Reference Citation Analysis]
34 Zuo X, Liu D. Progress in the application of minimal residual disease detection in multiple myeloma. J Hematopathol 2021;14:97-107. [DOI: 10.1007/s12308-020-00436-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer 2020;8:e000734. [PMID: 32661116 DOI: 10.1136/jitc-2020-000734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
36 Orlowski RZ, Lonial S. Integration of Novel Agents into the Care of Patients with Multiple Myeloma. Clin Cancer Res 2016;22:5443-52. [PMID: 28151712 DOI: 10.1158/1078-0432.CCR-16-0861] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
37 Anderson KC. Progress and Paradigms in Multiple Myeloma. Clin Cancer Res 2016;22:5419-27. [PMID: 28151709 DOI: 10.1158/1078-0432.CCR-16-0625] [Cited by in Crossref: 84] [Cited by in F6Publishing: 56] [Article Influence: 21.0] [Reference Citation Analysis]
38 Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, García-Sánchez O, Corral-Mateos A, Burgos L, Blanco E, Hernández-Martín J, Pontes R, Díez-Campelo M, Millacoy P, Rodríguez-Otero P, Prosper F, Merino J, Vidriales MB, García-Sanz R, Romero A, Palomera L, Ríos-Tamayo R, Pérez-Andrés M, Blanco JF, González M, van Dongen JJM, Durie B, Mateos MV, San-Miguel J, Orfao A; EuroFlow consortium. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018;8:117. [PMID: 30455467 DOI: 10.1038/s41408-018-0153-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
39 Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol 2022. [PMID: 35017721 DOI: 10.1038/s41571-021-00593-y] [Reference Citation Analysis]
40 Avet-loiseau H. Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons. American Society of Clinical Oncology Educational Book 2016. [DOI: 10.1200/edbk_159088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
41 Iftikhar A, Hassan H, Iftikhar N, Mushtaq A, Sohail A, Rosko N, Chakraborty R, Razzaq F, Sandeep S, Valent JN, Kanate AS, Anwer F. Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. Antibodies (Basel) 2019;8:E34. [PMID: 31544840 DOI: 10.3390/antib8020034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
42 Della Starza I, Chiaretti S, De Propris MS, Elia L, Cavalli M, De Novi LA, Soscia R, Messina M, Vitale A, Guarini A, Foà R. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. Front Oncol 2019;9:726. [PMID: 31448230 DOI: 10.3389/fonc.2019.00726] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
43 Wang G, Ning FY, Wang JH, Yan HM, Kong HW, Zhang YT, Shen Q. Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance. World J Clin Cases 2019; 7(24): 4234-4244 [PMID: 31911904 DOI: 10.12998/wjcc.v7.i24.4234] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Shires K, Wienand K. Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients. J Cancer Res Clin Oncol 2016;142:2383-96. [PMID: 27581737 DOI: 10.1007/s00432-016-2231-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
45 Cheng AC, Levy MA. Measures of Treatment Workload for Patients With Breast Cancer. JCO Clin Cancer Inform 2019;3:1-10. [PMID: 30715929 DOI: 10.1200/CCI.18.00122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Karki K, Harishchandra S, Safe S. Bortezomib Targets Sp Transcription Factors in Cancer Cells. Mol Pharmacol 2018;94:1187-96. [PMID: 30115673 DOI: 10.1124/mol.118.112797] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
47 Dempsey JL, Johns A, Rosko AE, Lazarus HM. The pharmacologic management of multiple myeloma in older adults. Expert Opin Pharmacother 2019;20:887-902. [PMID: 30785310 DOI: 10.1080/14656566.2019.1577822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Romano A, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C. Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives. Front Oncol 2019;9:699. [PMID: 31482061 DOI: 10.3389/fonc.2019.00699] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
49 Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia 2017;31:382-92. [PMID: 27479184 DOI: 10.1038/leu.2016.211] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
50 Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S. Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol 2017;8:55-70. [PMID: 28203342 DOI: 10.1177/2040620716680548] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
51 Paiva B, Corchete LA, Vidriales M, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez M, Barcena P, Echeveste M, Hernandez MT, García-sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos M, San Miguel JF. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood 2016;127:1896-906. [DOI: 10.1182/blood-2015-08-665679] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
52 Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N. Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). Leuk Lymphoma 2016;57:1256-68. [PMID: 26735310 DOI: 10.3109/10428194.2015.1131278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
53 Scarlata S, Annibali O, Santangelo S, Tomarchio V, Ferraro S, Armiento D, Scardocci A, Arcese W, Antonelli Incalzi R, Avvisati G. Pulmonary complications and survival after autologous stem cell transplantation: predictive role of pulmonary function and pneumotoxic medications. Eur Respir J 2017;49:1601902. [DOI: 10.1183/13993003.01902-2016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
54 Gupta S, Karandikar NJ, Ginader T, Bellizzi AM, Holman CJ. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters. Cytometry B Clin Cytom 2018;94:500-8. [PMID: 29316245 DOI: 10.1002/cyto.b.21624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Luoma S, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen T, Kakko S, Putkonen M, Ollikainen H, Terävä V, Sankelo M, Partanen A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Lievonen J, Selander T, Pelliniemi TT, Ilveskero S, Huotari V, Mäntymaa P, Tienhaara A, Jantunen E, Silvennoinen R. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group. Ann Hematol 2019;98:2781-92. [PMID: 31673775 DOI: 10.1007/s00277-019-03815-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
56 Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 2016;90:61-72. [PMID: 26100534 DOI: 10.1002/cyto.b.21265] [Cited by in Crossref: 115] [Cited by in F6Publishing: 94] [Article Influence: 16.4] [Reference Citation Analysis]
57 Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017;3:28-35. [PMID: 27632282 DOI: 10.1001/jamaoncol.2016.3160] [Cited by in Crossref: 228] [Cited by in F6Publishing: 213] [Article Influence: 45.6] [Reference Citation Analysis]
58 Takamatsu H. Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. Int J Hematol 2020;111:519-29. [DOI: 10.1007/s12185-020-02828-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Mainou M, Madenidou A, Liakos A, Paschos P, Karagiannis T, Bekiari E, Vlachaki E, Wang Z, Murad MH, Kumar S, Tsapas A. Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. Eur J Haematol 2017;98:563-8. [DOI: 10.1111/ejh.12868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bai Y, Wong KY, Fung TK, Chim CS. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. J Hematol Oncol 2016;9:107. [PMID: 27724958 DOI: 10.1186/s13045-016-0336-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
61 Hulin C, Beksac M, Goodman HJ, Spicka I, Alegre A, Prince M, Campana F, Finn G, Le-Guennec S, Macé S, Muccio S, Tavernier A, Rouchon MC, Richardson PG. Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. Blood Cancer J 2021;11:169. [PMID: 34671024 DOI: 10.1038/s41408-021-00562-9] [Reference Citation Analysis]
62 Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica 2019;104:1440-50. [PMID: 30733268 DOI: 10.3324/haematol.2018.202200] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
63 Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 2018;132:2456-64. [PMID: 30249784 DOI: 10.1182/blood-2018-06-858613] [Cited by in Crossref: 143] [Cited by in F6Publishing: 133] [Article Influence: 35.8] [Reference Citation Analysis]
64 Xiang X, He Q, Ou Y, Wang W, Wu Y. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. Front Pharmacol 2020;11:544754. [PMID: 33343342 DOI: 10.3389/fphar.2020.544754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Shang Y, Jin Y, Liu H, Ding L, Tong X, Tu H, Zang L, Lin C, Hu J, Zhou F. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. Hematol Oncol 2021. [PMID: 34860428 DOI: 10.1002/hon.2955] [Reference Citation Analysis]
66 Langerhorst P, Noori S, Zajec M, De Rijke YB, Gloerich J, van Gool AJ, Caillon H, Joosten I, Luider TM, Corre J, VanDuijn MM, Dejoie T, Jacobs JFM. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow. Clin Chem 2021;67:1689-98. [PMID: 34643690 DOI: 10.1093/clinchem/hvab187] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Takamatsu H, Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T, Murata R, Ueda M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol 2019;109:377-81. [PMID: 30778767 DOI: 10.1007/s12185-019-02615-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
68 Narita K, Miura D, Tsushima T, Terao T, Kuzume A, Tabata R, Takeuchi M, Matsue K. Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria. Sci Rep 2021;11:14956. [PMID: 34294772 DOI: 10.1038/s41598-021-94191-8] [Reference Citation Analysis]
69 Harousseau J, Avet-loiseau H. Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy. JCO 2017;35:2863-5. [DOI: 10.1200/jco.2017.73.1331] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
70 Roshal M. Measurable disease evaluation in patients with myeloma. Best Pract Res Clin Haematol 2020;33:101154. [PMID: 32139019 DOI: 10.1016/j.beha.2020.101154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Plesner T. Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab. J Clin Med 2021;10:1002. [PMID: 33801271 DOI: 10.3390/jcm10051002] [Reference Citation Analysis]
72 Katodritou E, Papadaki S, Konstantinidou P, Terpos E. Is it possible to cure myeloma without allogeneic transplantation? Transfus Apher Sci 2016;54:63-70. [PMID: 26850930 DOI: 10.1016/j.transci.2016.01.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
73 Came N. Should we be routinely testing for circulating clonal plasma cells in patients with multiple myeloma? Cytometry B Clin Cytom 2018;94:559. [PMID: 30240163 DOI: 10.1002/cyto.b.21741] [Reference Citation Analysis]
74 Yang PY, Liu MM, Fan HQ, Yang YP, Han W, Yu XY, Yue TT, Su KJ, Guo Q, Gao SJ, Jin FY. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:584-8. [PMID: 32397022 DOI: 10.3760/cma.j.issn.0253-2727.2019.07.009] [Reference Citation Analysis]
75 Yao Q, Bai Y, Orfao A, Chim CS. Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. Front Oncol 2019;9:449. [PMID: 31245284 DOI: 10.3389/fonc.2019.00449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
76 Sidiqi MH, Gertz MA. Daratumumab for the treatment of AL amyloidosis. Leuk Lymphoma 2019;60:295-301. [PMID: 30033840 DOI: 10.1080/10428194.2018.1485914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
77 Cordone I, Marchesi F, Masi S, Summa V, Pisani F, Merola R, Cigliana G, Orlandi G, Gumenyuk S, Palombi F, Romano A, Spadea A, Renzi D, Papa E, Canfora M, Conti L, Petti MC, Mengarelli A. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. J Exp Clin Cancer Res 2016;35:49. [PMID: 26992692 DOI: 10.1186/s13046-016-0324-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
78 Terpos E, Dimopoulos MA, Moulopoulos LA. The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. Am Soc Clin Oncol Educ Book 2016;35:e407-17. [PMID: 27249748 DOI: 10.1200/EDBK_159074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
79 Wang Y, Zong S, Li N, Wang Z, Chen B, Cui Y. SERS-based dynamic monitoring of minimal residual disease markers with high sensitivity for clinical applications. Nanoscale 2019;11:2460-7. [DOI: 10.1039/c8nr06929h] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
80 Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 2020;4:5988-99. [PMID: 33284948 DOI: 10.1182/bloodadvances.2020002827] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
81 Smith D, Yong K. Advances in understanding prognosis in myeloma. Br J Haematol 2016;175:367-80. [PMID: 27604166 DOI: 10.1111/bjh.14304] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
82 Bayly E, Nguyen V, Binek A, Piggin A, Baldwin K, Westerman D, Came N. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma. Cytometry B Clin Cytom 2020;98:385-98. [PMID: 32530574 DOI: 10.1002/cyto.b.21893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
83 An G, Yan Y, Xu Y, Mao X, Liu J, Fan H, Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D, Zhao Y, Yuan C, Du X, Wang J, Cheng T, Tai YT, Munshi NC, Qiu L. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia 2020;34:578-88. [PMID: 31591469 DOI: 10.1038/s41375-019-0590-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
84 van de Donk NW, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, Malavasi F, Avet-Loiseau H, Mateos MV, Sonneveld P, Lokhorst HM, Richardson PG. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 2016;127:681-95. [PMID: 26631114 DOI: 10.1182/blood-2015-10-646810] [Cited by in Crossref: 141] [Cited by in F6Publishing: 134] [Article Influence: 20.1] [Reference Citation Analysis]
85 Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, Delfau-Larue MH, Lhermitte L, Thieblemont C, Ribrag V, Cheze S, Sanhes L, Jardin F, Lefrère F, Delarue R, Hoster E, Dreyling M, Asnafi V, Hermine O, Macintyre E. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 2016;101:336-45. [PMID: 26703963 DOI: 10.3324/haematol.2015.134957] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
86 Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 2016;128:1174-80. [PMID: 27439911 DOI: 10.1182/blood-2016-03-707596] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 13.3] [Reference Citation Analysis]
87 Moor I, Bacher VU, Jeker B, Taleghani BM, Mueller BU, Keller P, Betticher D, Egger T, Novak U, Pabst T. Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma. Bone Marrow Transplant 2018;53:1599-602. [PMID: 29884856 DOI: 10.1038/s41409-018-0245-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
88 Patel DA, Gopalakrishnan R, Engelhardt BG, McArthur E, Sengsayadeth S, Culos KA, Byrne M, Goodman S, Savani BN, Chinratanalab W, Jagasia M, Mosse CA, Cornell RF, Kassim AA. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplant 2020;55:1137-46. [PMID: 31992845 DOI: 10.1038/s41409-020-0791-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
89 Cossarizza A, Chang HD, Radbruch A, Abrignani S, Addo R, Akdis M, Andrä I, Andreata F, Annunziato F, Arranz E, Bacher P, Bari S, Barnaba V, Barros-Martins J, Baumjohann D, Beccaria CG, Bernardo D, Boardman DA, Borger J, Böttcher C, Brockmann L, Burns M, Busch DH, Cameron G, Cammarata I, Cassotta A, Chang Y, Chirdo FG, Christakou E, Čičin-Šain L, Cook L, Corbett AJ, Cornelis R, Cosmi L, Davey MS, De Biasi S, De Simone G, Del Zotto G, Delacher M, Di Rosa F, Santo JD, Diefenbach A, Dong J, Dörner T, Dress RJ, Dutertre CA, Eckle SBG, Eede P, Evrard M, Falk CS, Feuerer M, Fillatreau S, Fiz-Lopez A, Follo M, Foulds GA, Fröbel J, Gagliani N, Galletti G, Gangaev A, Garbi N, Garrote JA, Geginat J, Gherardin NA, Gibellini L, Ginhoux F, Godfrey DI, Gruarin P, Haftmann C, Hansmann L, Harpur CM, Hayday AC, Heine G, Hernández DC, Herrmann M, Hoelsken O, Huang Q, Huber S, Huber JE, Huehn J, Hundemer M, Hwang WYK, Iannacone M, Ivison SM, Jäck HM, Jani PK, Keller B, Kessler N, Ketelaars S, Knop L, Knopf J, Koay HF, Kobow K, Kriegsmann K, Kristyanto H, Krueger A, Kuehne JF, Kunze-Schumacher H, Kvistborg P, Kwok I, Latorre D, Lenz D, Levings MK, Lino AC, Liotta F, Long HM, Lugli E, MacDonald KN, Maggi L, Maini MK, Mair F, Manta C, Manz RA, Mashreghi MF, Mazzoni A, McCluskey J, Mei HE, Melchers F, Melzer S, Mielenz D, Monin L, Moretta L, Multhoff G, Muñoz LE, Muñoz-Ruiz M, Muscate F, Natalini A, Neumann K, Ng LG, Niedobitek A, Niemz J, Almeida LN, Notarbartolo S, Ostendorf L, Pallett LJ, Patel AA, Percin GI, Peruzzi G, Pinti M, Pockley AG, Pracht K, Prinz I, Pujol-Autonell I, Pulvirenti N, Quatrini L, Quinn KM, Radbruch H, Rhys H, Rodrigo MB, Romagnani C, Saggau C, Sakaguchi S, Sallusto F, Sanderink L, Sandrock I, Schauer C, Scheffold A, Scherer HU, Schiemann M, Schildberg FA, Schober K, Schoen J, Schuh W, Schüler T, Schulz AR, Schulz S, Schulze J, Simonetti S, Singh J, Sitnik KM, Stark R, Starossom S, Stehle C, Szelinski F, Tan L, Tarnok A, Tornack J, Tree TIM, van Beek JJP, van de Veen W, van Gisbergen K, Vasco C, Verheyden NA, von Borstel A, Ward-Hartstonge KA, Warnatz K, Waskow C, Wiedemann A, Wilharm A, Wing J, Wirz O, Wittner J, Yang JHM, Yang J. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur J Immunol 2021;51:2708-3145. [PMID: 34910301 DOI: 10.1002/eji.202170126] [Reference Citation Analysis]
90 Tschautscher MA, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Russell SJ, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Vincent Rajkumar S, Kumar S. Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer J 2020;10:95. [PMID: 33009363 DOI: 10.1038/s41408-020-00363-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Front Oncol 2020;10:860. [PMID: 32537439 DOI: 10.3389/fonc.2020.00860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
92 Olteanu H. Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. Surg Pathol Clin 2016;9:101-16. [PMID: 26940271 DOI: 10.1016/j.path.2015.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
93 Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34:985-1005. [PMID: 32055000 DOI: 10.1038/s41375-020-0734-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 36.0] [Reference Citation Analysis]
94 Came N, Nguyen V, Westerman D, Harrison S. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection. Br J Haematol 2016;173:947-9. [DOI: 10.1111/bjh.13655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
95 Fulciniti M, Munshi NC, Martinez-Lopez J. Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int 2015;2015:832049. [PMID: 26783530 DOI: 10.1155/2015/832049] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
96 Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM. Circulating microRNAs and Their Role in Multiple Myeloma. Noncoding RNA 2019;5:E37. [PMID: 31052608 DOI: 10.3390/ncrna5020037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Chatterjee G, Gujral S, Subramanian PG, Tembhare PR. Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian J Hematol Blood Transfus 2017;33:303-15. [PMID: 28824230 DOI: 10.1007/s12288-017-0822-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
98 Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bellò M, Rambaldi I, Tacchetti P, Hillengass J, Gamberi B, Pantani L, Magarotto V, Versari A, Offidani M, Zannetti B, Carobolante F, Balma M, Musto P, Rensi M, Mancuso K, Dimitrakopoulou-strauss A, Chauviè S, Rocchi S, Fard N, Marzocchi G, Storto G, Ghedini P, Palumbo A, Fanti S, Cavo M. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 2016;30:417-22. [DOI: 10.1038/leu.2015.291] [Cited by in Crossref: 83] [Cited by in F6Publishing: 60] [Article Influence: 11.9] [Reference Citation Analysis]
99 Wang H, Lin P. Flow Cytometric Immunophenotypic Analysis in the Diagnosis and Prognostication of Plasma Cell Neoplasms. Cytometry 2018;96:338-50. [DOI: 10.1002/cyto.b.21844] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
100 Yin Y, Yang W, Zhang L, Liu K, Luo Z. Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma. Hematology 2021;26:160-9. [PMID: 33528317 DOI: 10.1080/16078454.2021.1872275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Milani P, Merlini G, Palladini G. What does minimal residual disease mean in AL amyloidosis? Expert Opinion on Orphan Drugs 2018;6:703-5. [DOI: 10.1080/21678707.2018.1549482] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
102 Paiva B, Merino J, San Miguel JF. Utility of flow cytometry studies in the management of patients with multiple myeloma. Curr Opin Oncol 2016;28:511-7. [PMID: 27606694 DOI: 10.1097/CCO.0000000000000331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
103 Zajec M, Langerhorst P, VanDuijn MM, Gloerich J, Russcher H, van Gool AJ, Luider TM, Joosten I, de Rijke YB, Jacobs JFM. Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins. Clin Chem 2020;66:421-33. [PMID: 32031591 DOI: 10.1093/clinchem/hvz041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
104 Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, Kumar SK. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. Am J Hematol 2018;93:889-94. [DOI: 10.1002/ajh.25113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
105 Sales MM, Ferreira SIACP, Ikoma MRV, Sandes AF, Beltrame MP, Bacal NS, Silva MCA, Malvezzi M, Lorand-Metze IGH, Orfao A, Yamamoto M; GBCFLUX. Diagnosis of chronic lymphoproliferative disorders by flow cytometry using four-color combinations for immunophenotyping: A proposal of the brazilian group of flow cytometry (GBCFLUX). Cytometry B Clin Cytom 2017;92:398-410. [PMID: 27362793 DOI: 10.1002/cyto.b.21396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
106 Bao HY, Wang Y, Wang JN, Song M, Meng QQ, Han X. [Clinical significance of S100A6 and Notch1 in multiple myeloma patients]. Zhonghua Xue Ye Xue Za Zhi 2017;38:285-9. [PMID: 28468088 DOI: 10.3760/cma.j.issn.0253-2727.2017.04.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
107 Smith BD, Dezern AE, Bastian AW, Durie BGM. Meaningful endpoints for therapies approved for hematologic malignancies: Endpoints for Hematologic Malignancies. Cancer 2017;123:1689-94. [DOI: 10.1002/cncr.30622] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
108 Oberle A, Brandt A, Voigtlaender M, Thiele B, Radloff J, Schulenkorf A, Alawi M, Akyüz N, März M, Ford CT, Krohn-Grimberghe A, Binder M. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica 2017;102:1105-11. [PMID: 28183851 DOI: 10.3324/haematol.2016.161414] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 11.2] [Reference Citation Analysis]
109 Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, Martinez-Lopez J, Rosiñol L, Gutierrez NC, Martín-Ramos ML, Oriol A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De la Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol 2017;35:2900-10. [PMID: 28498784 DOI: 10.1200/JCO.2016.69.2517] [Cited by in Crossref: 141] [Cited by in F6Publishing: 68] [Article Influence: 28.2] [Reference Citation Analysis]
110 Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, Jimenez C, González M, Martínez-López J, Corral-Mateos A, Grigore GE, Fluxá R, Pontes R, Caetano J, Sedek L, Del Cañizo MC, Bladé J, Lahuerta JJ, Aguilar C, Bárez A, García-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJM, Orfao A. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31:2094-103. [PMID: 28104919 DOI: 10.1038/leu.2017.29] [Cited by in Crossref: 239] [Cited by in F6Publishing: 232] [Article Influence: 47.8] [Reference Citation Analysis]
111 Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol 2017;2017:4812637. [PMID: 28321258 DOI: 10.1155/2017/4812637] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
112 Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res 2021;20:3134-49. [PMID: 34014671 DOI: 10.1021/acs.jproteome.1c00022] [Reference Citation Analysis]
113 Ziogas DC, Dimopoulos MA, Kastritis E. Prognostic factors for multiple myeloma in the era of novel therapies. Expert Review of Hematology 2018;11:863-79. [DOI: 10.1080/17474086.2018.1537776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
114 Sanoja-Flores L, Flores-Montero J, Pérez-Andrés M, Puig N, Orfao A. Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications. Cancers (Basel) 2020;12:E1499. [PMID: 32521788 DOI: 10.3390/cancers12061499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
115 Roshal M, Flores-Montero JA, Gao Q, Koeber M, Wardrope J, Durie BGM, Dogan A, Orfao A, Landgren O. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv 2017;1:728-32. [PMID: 29296716 DOI: 10.1182/bloodadvances.2016003715] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
116 Nakamura N, Maruyama D, Machida R, Ichinohe T, Takayama N, Ohba R, Ohmachi K, Imaizumi Y, Tokunaga M, Katsuya H, Yoshida I, Sunami K, Kurosawa M, Kubota N, Morimoto H, Kobayashi M, Kato H, Kameoka Y, Kagami Y, Kizaki M, Takeuchi K, Munakata W, Iida S, Nagai H. Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1). Jpn J Clin Oncol 2021;51:1059-66. [PMID: 33959770 DOI: 10.1093/jjco/hyab066] [Reference Citation Analysis]
117 Roshal M. Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How? Semin Hematol 2018;55:4-12. [PMID: 29759152 DOI: 10.1053/j.seminhematol.2018.02.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
118 Ding T, Deng R, Huang T. Long non-coding RNA T cell factor 7 is associated with increased disease risk and poor prognosis, and promotes cell proliferation, attenuates cell apoptosis and miR-200c expression in multiple myeloma. Oncol Lett 2021;21:129. [PMID: 33552250 DOI: 10.3892/ol.2020.12390] [Reference Citation Analysis]
119 Biancon G, Gimondi S, Vendramin A, Carniti C, Corradini P. Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot Study. J Mol Diagn 2018;20:859-70. [PMID: 30165206 DOI: 10.1016/j.jmoldx.2018.07.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
120 Michallet M, Chapuis-Cellier C, Dejoie T, Lombard C, Caillon H, Sobh M, Moreau P, Attal M, Avet-Loiseau H. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia 2018;32:376-82. [PMID: 28663581 DOI: 10.1038/leu.2017.209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
121 Gao Q, Yellapantula V, Fenelus M, Pichardo J, Wang L, Landgren O, Dogan A, Roshal M. Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. Mod Pathol 2018;31:881-9. [PMID: 29403080 DOI: 10.1038/s41379-018-0011-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
122 Detappe A, Bustoros M, Mouhieddine TH, Ghoroghchian PP. Advancements in Nanomedicine for Multiple Myeloma. Trends in Molecular Medicine 2018;24:560-74. [DOI: 10.1016/j.molmed.2018.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
123 Flach J, Shumilov E, Joncourt R, Porret N, Novak U, Pabst T, Bacher U. Current concepts and future directions for hemato-oncologic diagnostics. Critical Reviews in Oncology/Hematology 2020;151:102977. [DOI: 10.1016/j.critrevonc.2020.102977] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
124 Okura M, Ida N, Yamauchi T. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era. Med Oncol 2020;37:103. [PMID: 33068194 DOI: 10.1007/s12032-020-01423-4] [Reference Citation Analysis]
125 Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, Murata R, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol. 2017;28:2503-2510. [PMID: 28945825 DOI: 10.1093/annonc/mdx340] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
126 Shires K, Wyk TV, Wienand K. The expression of multiple cancer/testis antigens can potentially be used to detect circulating disease and clonal evolution in the peripheral blood of multiple myeloma patients. Blood Res 2021;56:156-65. [PMID: 34462402 DOI: 10.5045/br.2021.2020335] [Reference Citation Analysis]
127 Lee H, Duggan P, Neri P, Tay J, Bahlis NJ, Jimenez-Zepeda VH. Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet? Bone Marrow Transplant 2017;52:915-7. [PMID: 28287637 DOI: 10.1038/bmt.2017.28] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
128 Kastritis E, Kostopoulos IV, Theodorakakou F, Fotiou D, Gavriatopoulou M, Migkou M, Tselegkidi MI, Roussou M, Papathoma A, Eleutherakis-Papaioakovou E, Dialoupi I, Kanellias N, Ntalianis A, Rousakis P, Trougakos IP, Tsitsilonis O, Gakiopoulou C, Terpos E, Dimopoulos MA. Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid 2021;28:19-23. [PMID: 32783569 DOI: 10.1080/13506129.2020.1802713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
129 Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Wilson JN, Jenner MW, Cook G, Kaiser MF, Drayson MT, Owen RG, Russell NH, Gregory WM, Morgan GJ; UK NCRI Haematological Oncology Clinical Studies Group. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol 2019;6:e616-29. [PMID: 31624047 DOI: 10.1016/S2352-3026(19)30167-X] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
130 Moreno-Cubero E, Subirá D, Sanz-de-Villalobos E, Parra-Cid T, Madejón A, Miquel J, Olveira A, González-Praetorius A, García-Samaniego J, Larrubia JR. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity. J Virol 2018;92:e01443-17. [PMID: 29093082 DOI: 10.1128/JVI.01443-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
131 Czyż J, Małkowski B, Jurczyszyn A, Grząśko N, Łopatto R, Olejniczak M, Czyż A, Jachalska A. 18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. Contemp Oncol (Pozn) 2019;23:23-31. [PMID: 31061633 DOI: 10.5114/wo.2019.83342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Chitty DW, Hartley-Brown MA, Abate M, Thakur R, Wanchoo R, Jhaveri KD, Nair V. Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last 2 decades. Nephrol Dial Transplant 2020:gfaa361. [PMID: 33295615 DOI: 10.1093/ndt/gfaa361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
133 Kapoor P, Rajkumar SV. Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Nat Rev Clin Oncol 2017;14:73-4. [PMID: 28071678 DOI: 10.1038/nrclinonc.2016.221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
134 Soliman AM, Das S, Teoh SL. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis. Int J Mol Sci 2021;22:7470. [PMID: 34299097 DOI: 10.3390/ijms22147470] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Innao V, Allegra A, Russo S, Gerace D, Vaddinelli D, Alonci A, Allegra AG, Musolino C. Standardisation of minimal residual disease in multiple myeloma. Eur J Cancer Care (Engl) 2017;26. [PMID: 28671297 DOI: 10.1111/ecc.12732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
136 Ševčíková T, Growková K, Kufová Z, Filipová J, Vrublová P, Jelínek T, Kořístek Z, Kryukov F, Kryukova E, Hájek R. Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. J Clin Pathol 2017;70:847-53. [PMID: 28360189 DOI: 10.1136/jclinpath-2017-204329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
137 Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:719-34. [PMID: 27291302 DOI: 10.1002/ajh.24402] [Cited by in Crossref: 241] [Cited by in F6Publishing: 228] [Article Influence: 48.2] [Reference Citation Analysis]
138 Sidiqi MH, Aljama MA, Jevremovic D, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz MA. Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biol Blood Marrow Transplant 2018;24:2360-4. [PMID: 29964192 DOI: 10.1016/j.bbmt.2018.06.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
139 Palladini G, Paiva B, Wechalekar A, Massa M, Milani P, Lasa M, Ravichandran S, Krsnik I, Basset M, Burgos L, Nuvolone M, Lecumberri R, Foli A, Puig N, Sesta MA, Bozzola M, Cascino P, Nevone A, Ripepi J, Berti P, Casarini S, Annibali O, Orfao A, San-Miguel J, Merlini G. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J 2021;11:34. [PMID: 33594045 DOI: 10.1038/s41408-021-00428-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
140 Márk Á, Varga G, Timár B, Kriston C, Szabó O, Deák L, Matolcsy A, Barna G. The effect of microenvironmental factors on the development of myeloma cells. Hematol Oncol 2017;35:741-5. [PMID: 27766647 DOI: 10.1002/hon.2354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Singh G. Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results. J Clin Med Res 2017;9:671-9. [PMID: 28725315 DOI: 10.14740/jocmr3049w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
142 Firer MA, Shapira MY, Luboshits G. The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma. Cancers (Basel) 2021;13:4090. [PMID: 34439244 DOI: 10.3390/cancers13164090] [Reference Citation Analysis]
143 Gupta R, Kumar L, Dahiya M, Mathur N, Harish P, Sharma A, Sharma OD, Shekhar V. Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma. Leuk Lymphoma. 2017;58:1234-1237. [PMID: 27658735 DOI: 10.1080/10428194.2016.1228930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
144 Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PLoS One 2020;15:e0237155. [PMID: 32866200 DOI: 10.1371/journal.pone.0237155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Qasaimeh MA, Wu YC, Bose S, Menachery A, Talluri S, Gonzalez G, Fulciniti M, Karp JM, Prabhala RH, Karnik R. Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. Sci Rep 2017;7:45681. [PMID: 28374831 DOI: 10.1038/srep45681] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
146 Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. Cells 2020;9:E2666. [PMID: 33322499 DOI: 10.3390/cells9122666] [Reference Citation Analysis]
147 Mizuta S, Kawata T, Kawabata H, Yamane N, Mononobe S, Komai T, Koba Y, Ukyo N, Tamekane A, Watanabe M. VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era. Int J Hematol 2019;110:322-30. [DOI: 10.1007/s12185-019-02685-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
148 Scherer F, Kurtz DM, Diehn M, Alizadeh AA. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood 2017;130:440-52. [PMID: 28600337 DOI: 10.1182/blood-2017-03-735639] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
149 Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J Clin Med 2019;8:E997. [PMID: 31323969 DOI: 10.3390/jcm8070997] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
150 Tan D, Lee JH, Chen W, Shimizu K, Hou J, Suzuki K, Nawarawong W, Huang SY, Sang Chim C, Kim K, Kumar L, Malhotra P, Chng WJ, Durie B; Asian Myeloma Network. Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Leuk Lymphoma 2018;59:2305-17. [PMID: 29390932 DOI: 10.1080/10428194.2018.1427858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
151 Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-46. [PMID: 27511158 DOI: 10.1016/S1470-2045(16)30206-6] [Cited by in Crossref: 888] [Cited by in F6Publishing: 439] [Article Influence: 177.6] [Reference Citation Analysis]
152 Mayerhoefer ME, Archibald SJ, Messiou C, Staudenherz A, Berzaczy D, Schöder H. MRI and PET/MRI in hematologic malignancies. J Magn Reson Imaging 2020;51:1325-35. [PMID: 31260155 DOI: 10.1002/jmri.26848] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
153 Joffe E, Iasonos A, Younes A. Clinical Trials in the Genomic Era. J Clin Oncol 2017;35:1011-7. [PMID: 28297622 DOI: 10.1200/JCO.2016.70.8891] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
154 Levin A, Hari P, Dhakal B. Novel biomarkers in multiple myeloma. Transl Res 2018;201:49-59. [PMID: 30301522 DOI: 10.1016/j.trsl.2018.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
155 Kamiya Y, Chou T, Murakami H, Handa H, Ozaki S, Shimazaki C, Fuchida SI, Okada J, Itoh J, Sugiyama S, Shimizu K. Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay. Hematol Oncol 2019;37:316-8. [PMID: 30938836 DOI: 10.1002/hon.2611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Am J Hematol 2019;94:751-6. [PMID: 30945330 DOI: 10.1002/ajh.25481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
157 Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF; Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 2016;127:3165-74. [PMID: 27118453 DOI: 10.1182/blood-2016-03-705319] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 14.0] [Reference Citation Analysis]
158 Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, Jenner M, Cook G, Drayson M, Owen R, Gregory W, Morgan G, Jackson G, Kaiser M. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol 2021;193:551-5. [PMID: 32524584 DOI: 10.1111/bjh.16793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
159 Zhang L, Beasley S, Prigozhina NL, Higgins R, Ikeda S, Lee FY, Marrinucci D, Jia S. Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma. J Circ Biomark 2016;5:10. [PMID: 28936258 DOI: 10.5772/64124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
160 Alonso R, Cedena MT, Gómez-Grande A, Ríos R, Moraleda JM, Cabañas V, Moreno MJ, López-Jiménez J, Martín F, Sanz A, Valeri A, Jiménez A, Sánchez R, Lahuerta JJ, Martínez-López J. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol 2019;94:853-61. [PMID: 31074033 DOI: 10.1002/ajh.25507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
161 Yoroidaka T, Narita K, Takamatsu H, Fujisawa M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods. Sci Rep 2021;11:11218. [PMID: 34045494 DOI: 10.1038/s41598-021-89761-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
162 Fulciniti M, Amodio N, Cea M, Maiso P, Azab AK. Biological Insights into Myeloma and Other B Cell Malignancies. Biomed Res Int 2016;2016:5218093. [PMID: 26989685 DOI: 10.1155/2016/5218093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
163 Yoshida T, Ri M, Kinoshita S, Narita T, Totani H, Ashour R, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. PLoS One 2018;13:e0196780. [PMID: 29738534 DOI: 10.1371/journal.pone.0196780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
164 Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J Hematol 2016;91:90-100. [PMID: 26565896 DOI: 10.1002/ajh.24236] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 15.7] [Reference Citation Analysis]
165 Zamagni E, Tacchetti P, Terragna C, Cavo M. Multiple myeloma: disease response assessment. Expert Review of Hematology 2016;9:831-7. [DOI: 10.1080/17474086.2016.1212654] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
166 Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Ann Hematol 2017;96:441-8. [PMID: 27913860 DOI: 10.1007/s00277-016-2888-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
167 Gonsalves WI, Rajkumar SV, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa YL, Kourelis TV, Kyle RA, Kumar SK. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplant 2016;51:1156-8. [DOI: 10.1038/bmt.2016.91] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
168 Dogliotti I, Drandi D, Genuardi E, Ferrero S. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies. J Clin Med 2018;7:E288. [PMID: 30231510 DOI: 10.3390/jcm7090288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
169 Baghdadi M, Ishikawa K, Nakanishi S, Murata T, Umeyama Y, Kobayashi T, Kameda Y, Endo H, Wada H, Bogen B, Yamamoto S, Yamaguchi K, Kasahara I, Iwasaki H, Takahata M, Ibata M, Takahashi S, Goto H, Teshima T, Seino KI. A role for IL-34 in osteolytic disease of multiple myeloma. Blood Adv 2019;3:541-51. [PMID: 30782613 DOI: 10.1182/bloodadvances.2018020008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
170 Wang XF, Wang TT, Zhang ZY, Zhou HX, Zhang YR, Chen WM, Geng CY. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry]. Zhonghua Xue Ye Xue Za Zhi 2019;40:512-7. [PMID: 31340626 DOI: 10.3760/cma.j.issn.0253-2727.2019.06.012] [Reference Citation Analysis]
171 Diaz-pallares C, Lee H, Luider J, Duggan P, Neri P, Tay J, Macculloch S, Bahlis NJ, Jimenez-zepeda VH. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes. Clinical Lymphoma Myeloma and Leukemia 2020;20:394-9. [DOI: 10.1016/j.clml.2019.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
172 Steinbach M, Richards T, Faiman B. Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients. Semin Oncol Nurs 2017;33:254-64. [PMID: 28683956 DOI: 10.1016/j.soncn.2017.05.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
173 Van der Straeten J, De Brouwer W, Kabongo E, Dresse MF, Fostier K, Schots R, Van Riet I, Bakkus M. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators. J Mol Diagn 2021;23:599-611. [PMID: 33549860 DOI: 10.1016/j.jmoldx.2021.01.009] [Reference Citation Analysis]
174 Pourmoussa AM, Spielberger R, Cai J, Khoshbin O, Farol L, Cao T, Sahebi F. Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant. Perm J 2019;23. [PMID: 31926575 DOI: 10.7812/TPP/19.012] [Reference Citation Analysis]
175 Kim SM, Lee Y, Jeong D, Yun J, Yoon SS, Hwang SM, Lee N, Lee DS. Significance of analyzing circulating plasma cells in multiple myeloma: differences from measuring minimal residual diseases in bone marrow. Leuk Lymphoma 2021;:1-4. [PMID: 34727831 DOI: 10.1080/10428194.2021.1992765] [Reference Citation Analysis]
176 Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, Omedè P. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget 2017;8:5924-35. [PMID: 27779105 DOI: 10.18632/oncotarget.12641] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]